Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.
Latest From Brexit
The European Medicines Agency has taken possession of its new HQ in Amsterdam and has hired 77 new staff members to make up for the severe staff losses it has witnessed on account of Brexit.
The UK pharma industry association has underscored the sector’s importance while outlining its demands for the country’s policy around medicines and R&D.
The BioIndustry Association has laid out its wishlist for the next UK administration, including deep regulatory alignment with the EU after Brexit, a more “flexible” approach to health technology assessment appraisals of new drugs, and support for R&D.
BSI Netherlands is the seventh notified body to be designated under the EU’s Medical Device Regulation. But this latest announcement is one of the most important yet.
Brexit and the NHS are likely to be key issues as political parties in the UK prepare to campaign ahead of the general election in December.
Risk management was the thread running through the ABHI’s annual regulatory conference. But the irrepressible theme of the MDR was the main draw for the 200 attendees, even though the MHRA and industry are still unaware of the shape of the UK’s future relationship with the EU.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.